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Introduction {#sec001}
============

Amyotrophic lateral sclerosis (ALS) is a progressive degeneration of motor neurons, involving the upper and lower motor neurons of the spinal cord, brainstem, and cerebral cortex, that causes disability and death within three to five years following diagnosis \[[@pone.0192243.ref001]--[@pone.0192243.ref003]\]. ALS is cartherized by stiff muscles and muscle twitching, which in the majority of cases causes a progressive weakness and wasting of muscles which control the movement, breathing, and swallowing \[[@pone.0192243.ref004]\]. Malnutrition has been associated with a linear decline in muscle strength which increases the risk of death in patients with ALS \[[@pone.0192243.ref005]--[@pone.0192243.ref007]\]. Specifically, ALS patients with severe malnutrition suffer from muscle atrophy, muscle weakness, and diaphragmatic paralysis \[[@pone.0192243.ref008], [@pone.0192243.ref009]\]. Therefore, effective nutritional care is particularly important in ALS patients.

Currently, gastrostomy that has shown to improve the disease prognosis, is widely used in ALS patients \[[@pone.0192243.ref010], [@pone.0192243.ref011]\]. Two commonly used approaches for percutaneous gastrostomy are radiologic and endoscopic methods \[[@pone.0192243.ref012]\]. According to the American Academy of Neurology, ALS Practice Parameter guidelines, ALS patients with symptomatic dysphagia and vital capacity exceeding 50% of the predicted value should undergo percutaneous endoscopic gastrostomy (PEG). Nevertheless, only 13% of patients are administered with PEG due to lack of sufficient evidence for the effectiveness of PEG in ALS patients \[[@pone.0192243.ref013]\]. A previous meta-analysis demonstrated undefined effects of PEG on survival due to limited evidence, while PEG tubes have been associated with prolonged life in older individuals \[[@pone.0192243.ref014]\]. However, there was limited evidence demonstrating that PEG prolongs the survival in ALS patients \[[@pone.0192243.ref004]\]. Although numerous studies have evaluated the therapeutic effects of PEG on survival in ALS patients, supportive high-quality clinical evidence is not available. Hence, a more robust analysis of all the available studies is highly necessary. Here, we attempted a large-scale examination of the available studies comparing PEG and other procedures with regard to the survival in ALS patients.

Materials and methods {#sec002}
=====================

Data sources, search strategy, and selection criteria {#sec003}
-----------------------------------------------------

This review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Statement guidelines issued in 2009 ([S1 Checklist](#pone.0192243.s001){ref-type="supplementary-material"}) \[[@pone.0192243.ref015]\]. The PubMed, EmBase, and Cochrane library were searched for articles assessing the effectiveness of PEG in ALS patients from the inception date to June 2017. The keywords used were the following: "(percutaneous endoscopic gastrostomy or PEG)" and "amyotrophic lateral sclerosis" or "sclerosis, amyotrophic lateral" or "Charcot disease" or "motor neuron disease". The detailed search strategy in PubMed was presented in **[S1 File](#pone.0192243.s002){ref-type="supplementary-material"}**. The search was limited to the articles published in English language. The abstracts and virtual meeting presentations were searched to identify for relevant unpublished studies. We also hand-searched the journals for published relevant data, as well as the reference lists of all the retrieved articles and relevant review articles.

The literature search was independently undertaken by two investigators using a standardized approach, while any inconsistencies were settled by the primary author. The inclusion criteria were: (1) study with prospective or retrospective design; (2) all included patients had ALS; (3) patients administered either with PEG or non-PEG interventions; (4) availability of survival rate in each group. Studies were excluded if: (1) patients were diagnosed with other diseases; (2) the study with inappropriate control; and (3) studies without adequate data.

Data collection and quality assessment {#sec004}
--------------------------------------

Data extraction and assessment were conducted independently by two investigators. Publication data (first author's name and publication year), study characteristics (country, study design, sample size, mean age, percentage male, intervention, and control), and survival rates at different follow-up durations were extracted. Disagreements were resolved by a third reviewer or consensus-based discussion. 30-day survival rate was the primary endpoint in the present meta-analysis study, while the secondary endpoints included 10-month, 20-month, and 30-month survival rates.

The Newcastle-Ottawa Scale (NOS), which is quite comprehensive and has been partially validated for evaluating the quality of observational studies in the meta-analysis, was used to assess the methodological quality \[[@pone.0192243.ref016]\]. NOS were based on the following 3 subscales: selection (4 items), comparability (1 item), and outcome (3 items). A "star system" (range, 0--9) was developed for assessment. The quality assessment was performed independently by two investigators. The data were examined and adjudicated independently by an additional investigator based on original reports.

Statistical analysis {#sec005}
--------------------

The therapeutic effects of PEG on survival were assessed based on the number of surviving patients and sample size in each group for every study. Odds ratios (ORs) with corresponding 95% confidence intervals (CIs) were employed as summary statistics with random-effects model. The results from the random-effects model imply that the true underlying effect varies across the included studies \[[@pone.0192243.ref017], [@pone.0192243.ref018]\]. Study heterogeneity was analyzed by Q statistics, with P\<0.10 denoting statistical significance. The degree of heterogeneity was based on the I^2^ statistics, with I^2^\>50% indicating significant heterogeneity and data with I^2^\>75% were not included in the final analysis \[[@pone.0192243.ref019], [@pone.0192243.ref020]\]. Sensitivity analysis was carried out by removing each individual study from the overall analysis to evaluate its influence on the obtained results \[[@pone.0192243.ref021]\]. Subgroup analyses were also conducted based on publication year, study design, sample size, mean age, and percentage of males. Furthermore, Chi-square test and meta-regression were used to assess various subgroups \[[@pone.0192243.ref022]\]. The Egger's \[[@pone.0192243.ref023]\] and Begg's \[[@pone.0192243.ref024]\] tests were used to statistically assess publication bias for major cardiovascular outcomes. Two-sided P\<0.05 was considered statistically significant. Statistical analyses were performed with the STATA software (version 12.0; Stata Corporation, College Station, TX, USA).

Results {#sec006}
=======

The study-selection process is shown in **[Fig 1](#pone.0192243.g001){ref-type="fig"}**. A total of 528 articles (187 from PubMed, 326 from EmBase, and 15 from Cochrane library) were retrieved during the initial electronic search, while 496 articles were irrelevant or duplicate, and thus were excluded. Meanwhile, 32 potentially eligible studies were selected. After detailed evaluation, 10 studies were selected for the final meta-analysis \[[@pone.0192243.ref010], [@pone.0192243.ref025]--[@pone.0192243.ref033]\]. Twenty-two studies were excluded due to the following reasons: survival rate data was not reported in 17 studies; three studies included patients with other interventions; and 2 studies reported sample patient population. A manual search of the reference lists of the latter studies yielded no further eligible studies. General characteristics of the included studies are presented in **[Table 1](#pone.0192243.t001){ref-type="table"}**.

![Flow diagram of the literature search and selection process.](pone.0192243.g001){#pone.0192243.g001}

10.1371/journal.pone.0192243.t001

###### Baseline characteristic of studies included in the systematic review and meta-analysis.

![](pone.0192243.t001){#pone.0192243.t001g}

  Study                                                Country           Study design    Sample size   Age    Percentage of males(%)   Intervention   Control      NOS score
  ---------------------------------------------------- ----------------- --------------- ------------- ------ ------------------------ -------------- ------------ -----------
  Shaw 2006 \[[@pone.0192243.ref025]\]                 UK                Retrospective   98            61.0   50.0                     PEG            RIG or NG    7
  Mathus-Vliegen 1994 \[[@pone.0192243.ref026]\]       The Netherlands   Prospective     68            57.0   48.5                     PEG            Other        7
  Mazzini 1995 \[[@pone.0192243.ref010]\]              Italy             Prospective     66            59.9   51.5                     PEG            Other        7
  Spataro 2011 \[[@pone.0192243.ref027]\]              Italy             Retrospective   150           60.5   55.3                     PEG            Other        8
  Blondet 2010 \[[@pone.0192243.ref028]\]              France            Retrospective   40            66.1   42.5                     PEG            PRG          7
  Thornton 2002 \[[@pone.0192243.ref029]\]             Ireland           Retrospective   36            54.0   52.8                     PEG            PRG          7
  Allen 2013 \[[@pone.0192243.ref030]\]                USA               Retrospective   108           60.6   59.3                     PEG            RIG          8
  Desport 2005 \[[@pone.0192243.ref031]\]              France            Prospective     50            65.9   52.0                     PEG            RIG          7
  ProGas Study Group 2015 \[[@pone.0192243.ref032]\]   UK                Prospective     330           64.4   55.0                     PEG            RIG or PIG   8
  Chio 2004 \[[@pone.0192243.ref033]\]                 Italy             Retrospective   50            67.0   50.0                     PEG            PRG          7

\*PEG, percutaneous endoscopic gastrostomy; RIG, radiological inserted gastrostomy; NG, nasogastric tube; PRG, percutaneous radiologic gastrostomy; PIG, per-oral image-guided gastrostomy; NOS, Newcastle-Ottawa Scale

Among 10 included studies (including a total of 996 ALS patients), 4 \[[@pone.0192243.ref010], [@pone.0192243.ref025]--[@pone.0192243.ref033]\] were prospective studies and 6 were retrospective trials. The mean age of ALS patients was 54.0--67.0 years, and 36--330 patients were included in each study. Two studies were conducted in UK \[[@pone.0192243.ref025], [@pone.0192243.ref032]\], 3 in Italy \[[@pone.0192243.ref010], [@pone.0192243.ref027], [@pone.0192243.ref033]\], 2 in France \[[@pone.0192243.ref028], [@pone.0192243.ref031]\], 1 in the Netherlands \[[@pone.0192243.ref026]\], 1 in Ireland \[[@pone.0192243.ref029]\], and 1 in USA \[[@pone.0192243.ref030]\]. Study quality was evaluated using the NOS scale. Three studies had a score of 8 \[[@pone.0192243.ref027], [@pone.0192243.ref030], [@pone.0192243.ref032]\], while 7 had a score of 7 \[[@pone.0192243.ref010], [@pone.0192243.ref025], [@pone.0192243.ref026], [@pone.0192243.ref028], [@pone.0192243.ref029], [@pone.0192243.ref031], [@pone.0192243.ref033]\], respectively.

The effects of PEG on 30-day survival rate in ALS patients was reported in ten studies. The summary OR indicated that PEG administration in ALS patients was not associated with 30-day survival rate (OR = 1.59; 95%CI 0.93--2.71; P = 0.092; **[Fig 2](#pone.0192243.g002){ref-type="fig"}**), and with no overt heterogeneity (I^2^ = 0.0%; P = 0.966). Sensitivity analysis was performed, and sequential removal of each study from the pooled analysis did not significantly affect the overall results of the meta-analysis (**[Table 2](#pone.0192243.t002){ref-type="table"}**). Furthermore, subgroup analysis data were consistent with the overall findings, and no pre-defined factors affected the therapeutic effects of PEG on 30-day survival rate (**[Table 3](#pone.0192243.t003){ref-type="table"}**). In addition, sample size, mean age, and gender were not considered as significant factors on 30-day survival rate (**[S1 Table](#pone.0192243.s003){ref-type="supplementary-material"}**). Finally, there was no significant publication bias among the included studies (P value for the Egger's test, 0.402; P value for the Begg's test, 0.754; **[Table 4](#pone.0192243.t004){ref-type="table"}**).

![Association of PEG use with 30-day survival rate.](pone.0192243.g002){#pone.0192243.g002}

10.1371/journal.pone.0192243.t002

###### Sensitivity analysis.

![](pone.0192243.t002){#pone.0192243.t002g}

  Outcomes                     Excluding study     OR and 95% CI       P value   Heterogeneity (%)   P value for heterogeneity
  ---------------------------- ------------------- ------------------- --------- ------------------- ---------------------------
  **30-day survival rate**     Shaw 2006           1.69 (0.95--3.03)   0.076     0.0                 0.955
  Mathus-Vliegen 1994          1.49 (0.84--2.65)   0.168               0.0       0.957               
  Mazzini 1995                 1.58 (0.91--2.73)   0.105               0.0       0.935               
  Spataro 2011                 1.59 (0.93--2.71)   0.092               0.0       0.966               
  Blondet 2010                 1.65 (0.95--2.87)   0.078               0.0       0.951               
  Thornton 2002                1.55 (0.89--2.68)   0.120               0.0       0.947               
  Allen 2013                   1.55 (0.86--2.79)   0.141               0.0       0.937               
  Desport 2005                 1.71 (0.98--3.00)   0.060               0.0       0.979               
  ProGas Study Group 2015      1.41 (0.76--2.61)   0.278               0.0       0.969               
  Chio 2004                    1.64 (0.94--2.86)   0.080               0.0       0.949               
  **10-month survival rate**   Shaw 2006           1.25 (0.65--2.39)   0.500     55.5                0.028
  Mathus-Vliegen 1994          1.28 (0.69--2.39)   0.434               54.9      0.030               
  Mazzini 1995                 1.17 (0.61--2.24)   0.641               54.7      0.031               
  Spataro 2011                 1.25 (0.69--2.25)   0.458               55.5      0.028               
  Blondet 2010                 1.12 (0.62--2.02)   0.709               50.0      0.051               
  Thornton 2002                1.09 (0.64--1.87)   0.741               41.8      0.100               
  Desport 2005                 1.44 (0.81--2.53)   0.212               44.6      0.082               
  ProGas Study Group 2015      1.18 (0.56--2.51)   0.660               56.2      0.025               
  Chio 2004                    1.38 (0.91--2.10)   0.125               20.2      0.269               
  **20-month survival rate**   Shaw 2006           1.94 (1.16--3.26)   0.012     0.0                 0.490
  Mathus-Vliegen 1994          2.04 (1.22--3.40)   0.006               0.0       0.514               
  Mazzini 1995                 1.68 (0.99--2.85)   0.055               0.0       0.832               
  Spataro 2011                 2.13 (1.16--3.92)   0.015               0.0       0.510               
  Blondet 2010                 1.86 (1.11--3.12)   0.018               0.0       0.545               
  Thornton 2002                2.02 (1.20--3.39)   0.008               0.0       0.497               
  Desport 2005                 2.18 (1.31--3.62)   0.003               0.0       0.762               
  **30-month survival rate**   Shaw 2006           1.25 (0.74--2.10)   0.409     0.0                 0.928
  Mathus-Vliegen 1994          1.28 (0.76--2.17)   0.352               0.0       0.913               
  Spataro 2011                 1.34 (0.61--2.97)   0.463               0.0       0.917               
  Blondet 2010                 1.22 (0.73--2.03)   0.451               0.0       0.993               
  Thornton 2002                1.32 (0.77--2.23)   0.310               0.0       0.929               
  Desport 2005                 1.30 (0.77--2.18)   0.320               0.0       0.923               

\*OR, odds ratio; CI, confidence interval

10.1371/journal.pone.0192243.t003

###### Subgroup analysis.

![](pone.0192243.t003){#pone.0192243.t003g}

  Outcomes                     Group              OR and 95%CI   P value   Heterogeneity (%)   P value for heterogeneity
  ---------------------------- ------------------ -------------- --------- ------------------- ---------------------------
  **30-day survival rate**     Publication year                                                
  2005 or after                1.48(0.78--2.78)   0.228          0.0       0.798               0.674
  Before 2005                  1.91(0.70--5.22)   0.210          0.0       0.905               
  Study design                                                                                 
  Prospective                  1.86(0.87--3.96)   0.108          0.0       0.723               0.562
  Retrospective                1.35(0.63--2.89)   0.436          0.0       0.947               
  Sample size                                                                                  
  100 or larger                2.06(0.89--4.77)   0.090          0.0       0.767               0.424
  \< 100                       1.32(0.66--2.65)   0.433          0.0       0.947               
  Mean age (years)                                                                             
  60 or older                  1.43(0.78--2.61)   0.250          0.0       0.878               0.456
  \< 60                        2.34(0.74--7.46)   0.149          0.0       0.972               
  Percentage male (%)                                                                          
  50 or larger                 1.55(0.86--2.81)   0.147          0.0       0.933               0.877
  \<50                         1.74(0.51--5.99)   0.378          0.0       0.469               
  **10-month survival rate**   Publication year                                                
  2005 or after                1.22(0.77--1.93)   0.398          14.4      0.322               1.000
  Before 2005                  1.06(0.25--4.54)   0.938          74.3      0.009               
  Study design                                                                                 
  Prospective                  1.17(0.77--1.79)   0.457          10.6      0.340               1.000
  Retrospective                1.28(0.34--4.81)   0.717          68.3      0.013               
  Sample size                                                                                  
  100 or larger                1.32(0.85--2.05)   0.217          0.0       0.859               1.000
  \< 100                       1.18(0.53--2.65)   0.685          62.4      0.014               
  Mean age (years)                                                                             
  60 or older                  0.96(0.45--2.05)   0.919          56.2      0.044               0.256
  \< 60                        1.91(0.80--4.59)   0.147          34.8      0.216               
  Percentage male (%)                                                                          
  50 or larger                 1.13(0.58--2.22)   0.721          56.6      0.032               0.577
  \<50                         1.69(0.52--5.52)   0.386          38.5      0.202               
  **20-month survival rate**   Publication year                                                
  2005 or after                1.74(0.95--3.18)   0.074          0.0       0.562               0.492
  Before 2005                  2.49(1.09--5.68)   0.031          0.0       0.381               
  Study design                                                                                 
  Prospective                  1.81(0.53--6.18)   0.344          48.3      0.145               0.929
  Retrospective                1.94(1.07--3.50)   0.028          0.0       0.902               
  Sample size                                                                                  
  100 or larger                1.71(0.76--3.87)   0.194          \-        \-                  0.677
  \< 100                       2.13(1.16--3.92)   0.015          0.0       0.510               
  Mean age (years)                                                                             
  60 or older                  1.74(0.95--3.18)   0.074          0.0       0.562               0.492
  \< 60                        2.49(1.09--5.68)   0.031          0.0       0.381               
  Percentage male (%)                                                                          
  50 or larger                 1.93(1.12--3.31)   0.018          0.0       0.422               0.859
  \<50                         2.16(0.71--6.58)   0.177          0.0       0.465               
  **30-month survival rate**   Publication year                                                
  2005 or after                1.33(0.76--2.32)   0.321          0.0       0.835               0.765
  Before 2005                  1.10(0.36--3.36)   0.872          0.0       0.861               
  Study design                                                                                 
  Prospective                  1.12(0.32--3.89)   0.858          0.0       0.875               0.822
  Retrospective                1.31(0.76--2.26)   0.333          0.0       0.824               
  Sample size                                                                                  
  100 or larger                1.23(0.65--2.35)   0.523          \-        \-                  0.870
  \< 100                       1.34(0.61--2.97)   0.463          0.0       0.917               
  Mean age (years)                                                                             
  60 or older                  1.33(0.76--2.32)   0.321          0.0       0.835               0.765
  \< 60                        1.10(0.36--3.36)   0.872          0.0       0.861               
  Percentage male (%)                                                                          
  50 or larger                 1.22(0.71--2.08)   0.474          0.0       0.971               0.635
  \<50                         1.73(0.45--6.70)   0.426          0.0       0.473               

\*OR, odds ratio; CI, confidence interval

10.1371/journal.pone.0192243.t004

###### Publication bias analysis.

![](pone.0192243.t004){#pone.0192243.t004g}

  Outcomes                     P value for the Egger's test   P value for the Begg's test
  ---------------------------- ------------------------------ -----------------------------
  **30-day survival rate**     0.402                          0.754
  **10-month survival rate**   0.546                          0.754
  **20-month survival rate**   0.816                          0.368
  **30-month survival rate**   0.460                          0.260

A total of 9 studies evaluated the effects of PEG on 10-month survival rate in ALS patients. Our results showed no significant association between PEG and 10-month survival rate (OR = 1.25; 95%CI 0.72--2.17; P = 0.436; [Fig 3](#pone.0192243.g003){ref-type="fig"}). Although substantial heterogeneity was observed in the magnitude of effects across studies (I^2^ = 49.3%; P = 0.046), sequential exclusion of each study from the pooled data did not affect the overall results (**[Table 2](#pone.0192243.t002){ref-type="table"}**). Furthermore, meta-regression analyses suggested that sample size, mean age, and gender (percentage of male patients) did not affect the 10-month survival rate (**[S1 Table](#pone.0192243.s003){ref-type="supplementary-material"}**). Findings of subgroup analysis were consistent with the overall analysis (**[Table 3](#pone.0192243.t003){ref-type="table"}**) and no publication bias was observed (P value for the Egger's test, 0.546; P value for the Begg's test, 0.754; **[Table 4](#pone.0192243.t004){ref-type="table"}**).

![Association of PEG use with 10-month survival rate.](pone.0192243.g003){#pone.0192243.g003}

A total of 7 studies assessed the effects of PEG on 20-month survival rate in ALS patients. Pooled analysis of 20-month survival rate indicated a beneficial effect of PEG compared with other procedures (OR = 1.97; 95%CI 1.21--3.21; P = 0.007; **[Fig 4](#pone.0192243.g004){ref-type="fig"}**). There was no significant heterogeneity among the included studies (I^2^ = 0.0%; P = 0.616). Sequential exclusion of each study from the pooled data did not affect the overall conclusion (**[Table 2](#pone.0192243.t002){ref-type="table"}**). The results of meta-regression analyses found that sample size, mean age, and gender (percentage of male patients) were not correlated with 20-month survival rate (**[S1 Table](#pone.0192243.s003){ref-type="supplementary-material"}**). Subgroup analysis suggested significant improvement in 20-month survival rate, which was prominent in studies published before 2005, and those with a retrospective design, sample size \<100, mean age \<60.0 years, and percentage of male patients ≥50.0% ([Table 3](#pone.0192243.t003){ref-type="table"}). Egger's (P = 0.816) and Begg's (P = 0.368) tests suggested no significant publication bias for 20-month survival rate (**[Table 4](#pone.0192243.t004){ref-type="table"}**).

![Association of PEG use and 20-month survival rate.](pone.0192243.g004){#pone.0192243.g004}

A total of 6 studies reported the effects of PEG on 30-month survival rate in ALS patients. Pooled analysis indicated that there was no association between PEG and 30-month survival rate (OR = 1.28; 95%CI 0.77--2.11; P = 0.338; **[Fig 5](#pone.0192243.g005){ref-type="fig"}**). Although no heterogeneity was detected across the included studies (I^2^ = 0.0%; P = 0.964), sensitivity analysis was conducted. After sequential exclusion of each study from the pooled analysis, the conclusion was not affected (**[Table 2](#pone.0192243.t002){ref-type="table"}**). Sample size, mean age, and gender (percentage of male patients) did not significantly affect the 30-month survival rate (**[S1 Table](#pone.0192243.s003){ref-type="supplementary-material"}**). There were no significant differences in 30-month survival rate based on subgroup analysis (**[Table 3](#pone.0192243.t003){ref-type="table"}**). No significant publication bias was observed among the included studies (P value for the Egger's test was 0.460; P value for the Begg's test was 0.260; **[Table 4](#pone.0192243.t004){ref-type="table"}**).

![Association of PEG use and 30-month survival rate.](pone.0192243.g005){#pone.0192243.g005}

Discussion {#sec007}
==========

The current meta-analysis explored the therapeutic effects of PEG and survival rates at different follow-up durations based on a total of 996 ALS patients with a broad range of ethnicities assessed in 4 prospective and 6 retrospective studies. The obtained results suggested that compared to control, PEG had no effect on 30-day, 10-month, and 30-month survival rates. Yet, PEG showed a significant increase in 20-month survival rates. Sensitivity and subgroup analysis findings were consistent with the overall analysis for 30-day, 10-month, and 30-month survival rates. The therapeutic effects of PEG on 20-month survival rate were outstanding in studies published before 2005, and in studies with a retrospective design, sample size \<100, mean age \<60.0 years, and percentage of male patients ≥ 50.0%.

Malnutrition is an independent prognostic factor for muscle weakness and death in patients with ALS. Both dysphagia and hypermetabolism are significant risk factors for malnutrition, and they remain to be a major problem in ALS patients \[[@pone.0192243.ref034]--[@pone.0192243.ref036]\]. Currently, enteral nutrition is widely used to treat dysphagia in ALS patients. Therefore, ALS patients with dysphagia undergo PEG as a routine procedure for nutrition improvement, although the effects of PEG on survival remain undefined. Shaw et al \[[@pone.0192243.ref025]\] have reported equivalent post-procedure survival rates between PEG and radiological inserted gastrostomy, which have been found to decrease the morbidity and mortality. Finally, poor survival rate was expectedly observed in the nasogastric tube group, even though most of the patients who participated in the study were in pre-terminal stages of ALS. Mathus-Vliegen et al \[[@pone.0192243.ref026]\] have suggested PEG is a successful and safe procedure in highly disabled ALS patients with respiratory compromise and far-advanced neurologic disease. Mazzini et al \[[@pone.0192243.ref010]\] have indicated that long-term PEG use is associated with significantly improved survival rate in ALS patients with bulbar involvement. The possible reason for this is that most ALS patients die at home due to broncho-pneumonic complications, while PEG is associated with low incidence of pneumonia and cachexia. Spataro et al \[[@pone.0192243.ref027]\] have retrospectively analyzed 150 ALS patients with dysphagia, and found that PEG significantly improved survival, with fewer side effects. Furthermore, another study has also suggested that patients with spinal-onset benefitted more compared to their bulbar-onset counterparts. Blondet et al \[[@pone.0192243.ref028]\] have suggested that percutaneous radiologic gastrostomy is more efficacious and well-tolerated compared to PEG in ALS patients, likely because PEG has been associated with an increased risk of respiratory decompensation in ALS patients. Thornton et al \[[@pone.0192243.ref029]\] have demonstrated that percutaneous radiologic gastrostomy is associated with increased success rate compared with PEG. Allen et al \[[@pone.0192243.ref030]\] have indicated that PEG significantly increased the risk of post-procedure aspiration, while no significant difference has been observed in 30-day survival rate between the PEG and radiologic gastrostomy groups. Desport et al \[[@pone.0192243.ref031]\] have found no significant difference between PEG and RIG in survival rates, revealing a higher failure rate in the PEG group compared to RIG group. A study by ProGas Study Group indicated no significant difference in the survival rate and adverse events among PEG, radiologically inserted gastrostomy, and per-oral image-guided gastrostomy \[[@pone.0192243.ref032]\]. Chio et al have demonstrated that percutaneous radiological gastrostomy is superior to PEG in terms of survival in ALS patients with moderate or severe respiratory impairment \[[@pone.0192243.ref033]\]. They also proposed the use of nasogastric tube in the percutaneous radiological gastrostomy procedures, which is considered more favorable in patients with masseter spasm as they cannot open the mouth. The important strengths of the present study involve comprehensive inclusion of relevant studies with larger statistical power compared with any individual study. In addition, this report was based on 10 studies that were conducted in different countries, and that have broad characteristics, suggesting the broad applicability of the present findings.

The present meta-analysis suggested that ALS patients receiving PEG were associated with higher incidence of 20-month survival, while no significant differences were observed for 30-day, 10-month, and 30-month survival rates. However, due to chance these results might not be enough to substantiate a causal relationship between the impact of PEG on survival rate at different follow-up durations. The possible reason for this could be that the pooled results were obtained from various included studies. During the planning stages, the treatment effect of PEG on survival rate should be conducted according to nutritional status, while most of the included studies did not provide the information regarding the nutritional status and other baseline characteristics of ALS patients. Furthermore, ALS patients can have hypermetabolism, thus the caloric requirements of patients can contribute to the lower energy intake than energy expenditure \[[@pone.0192243.ref037]\].

Although subgroup analysis suggested prominent therapeutic effects of PEG in studies published before 2005, and in studies with a retrospective design, sample size \<100, mean age \<60.0 years, and percentage of male patients ≥50.0% for 20-month survival rate in ALS patients, no significant difference between various subgroups was observed. The potential reason for the studies conducted before 2005 was associated with different nutritional status. In addition, our study patients from different countries were correlated with nutritional status, while all the included studies were conducted in highly developed countries. Additionally, the study design and sample size were correlated with evidence level and statistical power. Finally, these factors might disprove the significant impact on 20-month survival in ALS patients administered with PEG. Also, the number of studies included in these subsets was very small, with lower event rates than expected, yielding broad confidence intervals, i.e. no statistically significant differences.

The present study has few limitations which are as follows: (1) several important factors, including general characteristics and clinical conditions affecting the survival rates at different follow-up durations, were not adjusted; (2) based on the published studies, publication bias was an inevitable problem in this analysis; (3) pooled data were used for analysis (individual data were not available), which restricted us from performing a substantially detailed analyses with more comprehensive results.

In conclusion, the current findings suggest that PEG significantly increases 20-month survival rates in ALS patients, with no significant effect on 30-day, 10-month, and 30-month survival rates. These results are consistent, and PEG should be recommended for ALS patients. Future large scale randomized controlled trials are required to confirm the therapeutic effects of PEG on survival rates in ALS patients.
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